» Articles » PMID: 39482847

Evaluation of Real-world Efficacy of Mepolizumab on SNOT-22 Outcomes in Patients with Unified Airway Disease

Overview
Publisher Wiley
Date 2024 Nov 1
PMID 39482847
Authors
Affiliations
Soon will be listed here.
Citing Articles

Evaluation of real-world efficacy of mepolizumab on SNOT-22 outcomes in patients with unified airway disease.

Gonzalez-Perez R, Poza-Guedes P, Martin-Voso M, Sanchez-Machin I Clin Transl Allergy. 2024; 14(11):e70006.

PMID: 39482847 PMC: 11527812. DOI: 10.1002/clt2.70006.

References
1.
Phillips K, Hoehle L, Caradonna D, Gray S, Sedaghat A . Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis. Clin Otolaryngol. 2018; 43(5):1328-1334. DOI: 10.1111/coa.13177. View

2.
Fokkens W, Lund V, Hopkins C, Hellings P, Kern R, Reitsma S . European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600. View

3.
Bachert C, Luong A, Gevaert P, Mullol J, Smith S, Silver J . The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti-IL-5 Biologic Therapy. J Allergy Clin Immunol Pract. 2023; 11(9):2630-2641. DOI: 10.1016/j.jaip.2023.05.011. View

4.
Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado C, Colodenco F, Giavina-Bianchi P . Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022; 8(3). PMC: 9339769. DOI: 10.1183/23120541.00576-2021. View

5.
Gonzalez-Perez R, Poza-Guedes P, Martin-Voso M, Sanchez-Machin I . Evaluation of real-world efficacy of mepolizumab on SNOT-22 outcomes in patients with unified airway disease. Clin Transl Allergy. 2024; 14(11):e70006. PMC: 11527812. DOI: 10.1002/clt2.70006. View